deltatrials
Terminated PHASE2 INTERVENTIONAL NCT00322673

Study of XL999 in Patients With Acute Myeloid Leukemia (AML)

A Phase 2 Study of XL999 Administered Intravenously to Subjects With Acute Myeloid Leukemia

Sponsor: Symphony Evolution, Inc.

Conditions AML Acute Myeloid Leukemia
Interventions XL999
Updated 6 times since 2017 Last updated: Feb 18, 2010 Started: May 31, 2006 Primary completion: Nov 30, 2006 Completion: May 31, 2007
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study was terminated due to cardiac toxicities

Other terminated trials from Symphony Evolution, Inc.

More terminations from Symphony Evolution, Inc.

Listed as NCT00322673, this PHASE2 trial focuses on AML and Acute Myeloid Leukemia and remains terminated or withdrawn. Sponsored by Symphony Evolution, Inc., it has been updated 6 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotTerminated~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotTerminated~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotTerminated~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 24 months · monthly snapshotTerminated

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

  5. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE2

    First recorded

May 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Symphony Evolution, Inc.
Data source: Symphony Evolution, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations